MODEL STRATEGIES |

This model assesses costs and outcomes for admitted severe and critical Covid-19 patients from time of admission to discharge or death |

Four competing strategies are modelled: |

1. The "status quo" summarizes costs and outcomes for patients assuming no dexamethasone or remdesivir |

2. The "dexamethasone" comparator summarizes costs and outcomes for patients assuming dexamethasone at 6mg/day |

3. The "remdesivir" comparator summarizes costs and outcomes for patients assuming remdesivir at 100mg/day |

4. The "remdesivr plus dexamethasone" comparator summarizes costs and outcomes for patients assuming remdesivir at 100mg/day plus dexamethasone at 6mg/day |

MODEL OUTCOMES |

Cost: mean cost (general ward, ICU, dexamethasone and remdesivir as appropriate) per admitted patient from the health care provider's perspective |

Health outcomes: mean DALYs and deaths per admitted patient |

Other outcomes: mean ICU days and inpatient days per admitted patient |

Budget impact: mean costs (or savings) associated with intervention implementation |